<DOC>
	<DOC>NCT02180763</DOC>
	<brief_summary>The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.</brief_summary>
	<brief_title>Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Adult patients (≥ 18 years) Presenting with primary immunodeficiency Having received subcutaneous injections of immunoglobulin at home using an automatic pump for at least 1 month at the time of inclusion For whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of Gammanorm® 165 mg/mL at home Having signed an informed consent form Patient currently participating in another interventional study at the time of inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Primary Immunodeficiency, PID</keyword>
</DOC>